The National Institute for Health and Care Excellence (Nice) said it is "extremely disappointed" it will be unable to ...

Although AstraZeneca, Daiichi Sankyo and England’s drug cost watchdog have spent months trying to hash out a fair price for ...

Nice said it was ‘extremely disappointed’ it will be unable to recommend trastuzumab deruxtecan, sold under the brand name ...

In the talks both ourselves and NHS England continued to offer as much flexibility as possible, but despite the intervention of Secretary of State for Health Wes Streeting, the companies did not put ...

The UK's drug pricing body has affirmed its earlier decision not to recommend coverage of AstraZeneca and Daiichi Sankyo’s ...

VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...

A woman whose cancer has spread to her bones, back, pelvis and neck but has been denied a life-extending drug because she lives in Wales says she "wants a chance to live". Rachel Davies, 40, from ...

Merck said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently ...

AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...

Sumitomo Mitsui Trust Group Inc. grew its stake in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 13.1% in the 3rd quarter, according to the company in its most recent 13F filing with the ...

Rachel Davies, 40, from Swansea, was diagnosed with secondary breast cancer in 2021. The drug, called Enhertu, can give patients with a specific type of incurable breast cancer an extra six months ...